Novel vaccine compositions comprising immunostimulatory oligonucleotides
A vaccine composition, immunostimulatory technology, applied in the direction of drug combination, medical preparations containing active ingredients, microorganisms, etc., can solve problems such as toxicity or animal recurrence
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0087] The preparation of vaccine compositions comprising an oil phase is straightforward and requires the separation of an aqueous phase comprising the antigen, class P immunostimulatory oligonucleotides, and optionally a water-soluble emulsifier with an oil and optionally a fat-soluble emulsifier. The oil phase is mixed. The resulting mixture was emulsified.
[0088] Other components of the composition may include pharmaceutically acceptable excipients such as carriers, solvents and diluents, isotonic agents, buffers, stabilizers, preservatives, vasoconstrictors, antibacterial agents, antifungal agents agent and so on. Typical carriers, solvents and diluents include water, saline, dextrose, ethanol, glycerol, oils and the like. Representative isotonic agents include sodium chloride, dextrose, mannitol, sorbitol, lactose, and the like. Suitable stabilizers include gelatin, albumin, and the like.
[0089] As used herein, "pharmaceutically acceptable carrier" includes any a...
Embodiment 1
[0097] Example 1: Leishmania antigens
[0098] Fifty laboratory-bred male and female Beagle dogs were obtained from Marshall BioResources (NY), and 5 dogs were randomly assigned to each of the 10 groups (Table 1). The dogs were between 3 and 4 months old at the time of the first injection. Three injections were administered at 21 day intervals; injection sites were observed, and blood samples were collected at indicated intervals for testing. P-CpG of SEQ ID NO:8 was used in this study.
[0099] Table 1: Experimental design for Leishmania antigen studies in dogs
[0100]
[0101]
[0102] CpG-P oligonucleotides
[0103] Q-Quil A
[0104] C-cholesterol
[0105] MDP-muramoyl dipeptide
[0106] FML-fucose-mannose ligand
[0107] E-SA- -SA
[0108] PMBCs were isolated on day 1, day 7, day 28 and day 49. Isolated PBMC were cultured in (medium) and treated with FML (20 μg / ml), LICE (Leishmania infantum (Leishmania Infantum) crude extract, 17.5 μg / ml) and ConA (con...
Embodiment 2
[0115] Example 2: EHV antigens
[0116] animal
[0117] Cross-bred males and mares aged 11-12 months were divided into treatment groups containing 5 horses each. Horses were maintained in outdoor facilities during the vaccination phase. Because nearly all horses are exposed to EHV in early life, horses are not truly untreated. Use SN titers to select animals with low titers, however, previous exposures may affect interpretation of test results. Conventionally killed EHV-1 was used as antigen in this study.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More